ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

EBERHARDT W E E , DE RUYSSCHER D , WEDER W , et al . 2nd ESMO consensus conference in lung cancer: locally advanced stage Ⅲ non-small cell lung cancer [J ] . Ann Oncol , 2015 , 26 ( 8 ): 1573 - 1588 . DOI: 10.1093/annonc/mdv187 http://doi.org/10.1093/annonc/mdv187 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318411 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318411

ANTONIA S J , VILLEGAS A , DANIEL D , et al . Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . N Engl J Med , 2017 , 377 ( 20 ): 1919 - 1929 . DOI: 10.1056/NEJMoa1709937 http://doi.org/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937

BANG A , SCHOENFELD J D , SUN A Y . PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer [J ] . Transl Lung Cancer Res , 2019 , 8 ( Suppl 2 ): S139-S146.

FAIVRE-FINN C , VICENTE D , KURATA T , et al . Four-year survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-an update from the PACIFIC trial [J ] . J Thorac Oncol , 2021 , 16 ( 5 ): 860 - 867 . DOI: 10.1016/j.jtho.2020.12.015 http://doi.org/10.1016/j.jtho.2020.12.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000228 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000228

SPIGEL D R , FAIVRE-FINN C , GRAY J E , et al . Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . J Clin Oncol , 2022 , 40 ( 12 ): 1301 - 1311 . DOI: 10.1200/JCO.21.01308 http://doi.org/10.1200/JCO.21.01308 https://ascopubs.org/doi/10.1200/JCO.21.01308 https://ascopubs.org/doi/10.1200/JCO.21.01308

NAIDOO J , VANSTEENKISTE J F , FAIVRE-FINN C , et al . Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage Ⅲ NSCLC: a post-hoc analysis of the PACIFIC trial [J ] . Lung Cancer , 2022 , 166 : 84 - 93 . DOI: 10.1016/j.lungcan.2022.02.003 http://doi.org/10.1016/j.lungcan.2022.02.003 https://linkinghub.elsevier.com/retrieve/pii/S0169500222000435 https://linkinghub.elsevier.com/retrieve/pii/S0169500222000435

PANJE C M , LUPATSCH J E , BARBIER M , et al . A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage Ⅲ NSCLC responding to definitive radiochemotherapy in Switzerland [J ] . Ann Oncol , 2020 , 31 ( 4 ): 501 - 506 . DOI: 10.1016/j.annonc.2020.01.007 http://doi.org/10.1016/j.annonc.2020.01.007 https://linkinghub.elsevier.com/retrieve/pii/S0923753420359287 https://linkinghub.elsevier.com/retrieve/pii/S0923753420359287

WANG Y , ZHANG T , HUANG Y L , et al . Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage Ⅲ non-small cell lung cancer: a systematic review and meta-analysis [J ] . Int J Radiat Oncol Biol Phys , 2022 , 112 ( 5 ): 1154 - 1164 . DOI: 10.1016/j.ijrobp.2021.12.150 http://doi.org/10.1016/j.ijrobp.2021.12.150 https://linkinghub.elsevier.com/retrieve/pii/S0360301621034222 https://linkinghub.elsevier.com/retrieve/pii/S0360301621034222

OFFIN M , SHAVERDIAN N , RIMNER A , et al . Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage Ⅲ non-small cell lung cancers treated with chemoradiation and durvalumab [J ] . Radiother Oncol , 2020 , 149 : 205 - 211 . DOI: 10.1016/j.radonc.2020.04.047 http://doi.org/10.1016/j.radonc.2020.04.047 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302280 https://linkinghub.elsevier.com/retrieve/pii/S0167814020302280

SOCINSKI M A , ÖZGÜROĞLU M , VILLEGAS A , et al . Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage Ⅲ non-small cell lung cancer (PACIFIC) [J ] . Clin Lung Cancer , 2021 , 22 ( 6 ): 549 - 561 . DOI: 10.1016/j.cllc.2021.05.009 http://doi.org/10.1016/j.cllc.2021.05.009 https://linkinghub.elsevier.com/retrieve/pii/S1525730421001443 https://linkinghub.elsevier.com/retrieve/pii/S1525730421001443

KEIR M E , FRANCISCO L M , SHARPE A H . PD-1 and its ligands in T-cell immunity [J ] . Curr Opin Immunol , 2007 , 19 ( 3 ): 309 - 314 . DOI: 10.1016/j.coi.2007.04.012 http://doi.org/10.1016/j.coi.2007.04.012 https://linkinghub.elsevier.com/retrieve/pii/S0952791507000647 https://linkinghub.elsevier.com/retrieve/pii/S0952791507000647

KEIR M E , BUTTE M J , FREEMAN G J , et al . PD-1 and its ligands in tolerance and immunity [J ] . Annu Rev Immunol , 2008 , 26 : 677 - 704 . DOI: 10.1146/annurev.immunol.26.021607.090331 http://doi.org/10.1146/annurev.immunol.26.021607.090331 https://www.annualreviews.org/doi/10.1146/annurev.immunol.26.021607.090331 https://www.annualreviews.org/doi/10.1146/annurev.immunol.26.021607.090331

PAZ-ARES L , SPIRA A , RABEN D , et al . Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage Ⅲ non-small cell lung cancer in the PACIFIC trial [J ] . Ann Oncol , 2020 , 31 ( 6 ): 798 - 806 . DOI: 10.1016/j.annonc.2020.03.287 http://doi.org/10.1016/j.annonc.2020.03.287 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363742 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363742

TUFMAN A , NEUMANN J , MANAPOV F , et al . Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase Ⅲ German intergroup lung trial (GILT) [J ] . Lung Cancer , 2021 , 160 : 17 - 27 . DOI: 10.1016/j.lungcan.2021.07.008 http://doi.org/10.1016/j.lungcan.2021.07.008 https://linkinghub.elsevier.com/retrieve/pii/S0169500221004700 https://linkinghub.elsevier.com/retrieve/pii/S0169500221004700

DOVEDI S J , ADLARD A L , LIPOWSKA-BHALLA G , et al . Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade [J ] . Cancer Res , 2014 , 74 ( 19 ): 5458 - 5468 .

AREDO J V , MAMBETSARIEV I , HELLYER J A , et al . Durvalumab for stage & #x02162; EGFR -mutated NSCLC after definitive chemoradiotherapy [J ] . J Thorac Oncol , 2021 , 16 ( 6 ): 1030 - 1041 . DOI: 10.1016/j.jtho.2021.01.1628 http://doi.org/10.1016/j.jtho.2021.01.1628 https://linkinghub.elsevier.com/retrieve/pii/S1556086421017020 https://linkinghub.elsevier.com/retrieve/pii/S1556086421017020

TO K K W , FONG W , CHO W C S . Immunotherapy in treating EGFR -mutant lung cancer: current challenges and new strategies [J ] . Front Oncol , 2021 , 11 : 635007 . DOI: 10.3389/fonc.2021.635007 http://doi.org/10.3389/fonc.2021.635007 https://www.frontiersin.org/articles/10.3389/fonc.2021.635007/full https://www.frontiersin.org/articles/10.3389/fonc.2021.635007/full

BORGHAEI H , PAZ-ARES L , HORN L , et al . Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer [J ] . N Engl J Med , 2015 , 373 ( 17 ): 1627 - 1639 . DOI: 10.1056/NEJMoa1507643 http://doi.org/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643

LEE C K , MAN J , LORD S , et al . Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis [J ] . JAMA Oncol , 2018 , 4 ( 2 ): 210 - 216 . DOI: 10.1001/jamaoncol.2017.4427 http://doi.org/10.1001/jamaoncol.2017.4427 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4427 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.4427

HELLYER J A , AREDO J V , DAS M , et al . Role of consolidation durvalumab in patients with EGFR - and HER 2-mutant unresectable stage & #x02162; NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 5 ): 868 - 872 . DOI: 10.1016/j.jtho.2020.12.020 http://doi.org/10.1016/j.jtho.2020.12.020 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000447 https://linkinghub.elsevier.com/retrieve/pii/S1556086421000447

XING L G , WU G , WANG L H , et al . Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage Ⅲ epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial [J ] . Int J Radiat Oncol Biol Phys , 2021 , 109 ( 5 ): 1349 - 1358 . DOI: 10.1016/j.ijrobp.2020.11.026 http://doi.org/10.1016/j.ijrobp.2020.11.026 https://linkinghub.elsevier.com/retrieve/pii/S036030162034548X https://linkinghub.elsevier.com/retrieve/pii/S036030162034548X

AKAMATSU H , MURAKAMI H , HARADA H , et al . Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; west Japan oncology group 6911L [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): 1745 - 1752 . DOI: 10.1016/j.jtho.2021.05.019 http://doi.org/10.1016/j.jtho.2021.05.019 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021900 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021900

HOTTA K , SAEKI S , YAMAGUCHI M , et al . Gefitinib induction followed by chemoradiotherapy in EGFR -mutant, locally advanced non-small cell lung cancer: LOGIK0902/OLCSG0905 phase & #x02161; study [J ] . ESMO Open , 2021 , 6 ( 4 ): 100191 . DOI: 10.1016/j.esmoop.2021.100191 http://doi.org/10.1016/j.esmoop.2021.100191 https://linkinghub.elsevier.com/retrieve/pii/S2059702921001526 https://linkinghub.elsevier.com/retrieve/pii/S2059702921001526

DURM G A , JABBOUR S K , ALTHOUSE S K , et al . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer : Hoosier Cancer Research Network LUN 14-179[J ] . Cancer , 2020 , 126 ( 19 ): 4353 - 4361 . DOI: 10.1002/cncr.33083 http://doi.org/10.1002/cncr.33083 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33083 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33083

HUNG A , LEE K M , LYNCH J A , et al . Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage Ⅲ non-small cell lung cancer [J ] . BMC Cancer , 2021 , 21 ( 1 ): 824 . DOI: 10.1186/s12885-021-08577-y http://doi.org/10.1186/s12885-021-08577-y https://doi.org/10.1186/s12885-021-08577-y https://doi.org/10.1186/s12885-021-08577-y

ZHANG T , BI N , ZHOU Z M , et al . The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy [J ] . J Thorac Dis , 2020 , 12 ( 8 ): 4347 - 4356 . DOI: 10.21037/jtd-20-2137 http://doi.org/10.21037/jtd-20-2137 http://jtd.amegroups.com/article/view/42685/html http://jtd.amegroups.com/article/view/42685/html

SENAN S , OKAMOTO I , LEE G W , et al . Design and rationale for a phase Ⅲ, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer: the ADRIATIC study [J ] . Clin Lung Cancer , 2020 , 21 ( 2 ): e84-e88.

JAZIEH A R , ONAL H C , TAN D S W , et al . Real-world treatment patterns and clinical outcomes in patients with stage Ⅲ NSCLC: results of KINDLE, a multicountry observational study [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): 1733 - 1744 . DOI: 10.1016/j.jtho.2021.05.003 http://doi.org/10.1016/j.jtho.2021.05.003 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021742 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021742

ZHOU Q , CHEN M , WU G , et al . GEMSTONE-301: a phase Ⅲ clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage Ⅲ) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [J ] . Transl Lung Cancer Res , 2020 , 9 ( 5 ): 2008 - 2015 . DOI: 10.21037/tlcr-20-608 http://doi.org/10.21037/tlcr-20-608 http://tlcr.amegroups.com/article/view/41261/html http://tlcr.amegroups.com/article/view/41261/html

MYERS C J , LU B . Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues [J ] . Int J Radiat Oncol Biol Phys , 2017 , 99 ( 5 ): 1129 - 1136 . DOI: 10.1016/j.ijrobp.2017.06.2452 http://doi.org/10.1016/j.ijrobp.2017.06.2452 https://linkinghub.elsevier.com/retrieve/pii/S0360301617335186 https://linkinghub.elsevier.com/retrieve/pii/S0360301617335186

DU S S , ZHOU L , ALEXANDER G S , et al . PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes [J ] . J Thorac Oncol , 2018 , 13 ( 4 ): 510 - 520 . DOI: 10.1016/j.jtho.2017.12.002 http://doi.org/10.1016/j.jtho.2017.12.002 https://linkinghub.elsevier.com/retrieve/pii/S1556086417330812 https://linkinghub.elsevier.com/retrieve/pii/S1556086417330812

PETERS S , FELIP E , DAFNI U , et al . Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-the ETOP NICOLAS trial [J ] . Lung Cancer , 2019 , 133 : 83 - 87 . DOI: 10.1016/j.lungcan.2019.05.001 http://doi.org/10.1016/j.lungcan.2019.05.001 https://linkinghub.elsevier.com/retrieve/pii/S0169500219304416 https://linkinghub.elsevier.com/retrieve/pii/S0169500219304416

PILLAI R N , BEHERA M , OWONIKOKO T K , et al . Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature [J ] . Cancer , 2018 , 124 ( 2 ): 271 - 277 . DOI: 10.1002/cncr.31043 http://doi.org/10.1002/cncr.31043 https://onlinelibrary.wiley.com/doi/10.1002/cncr.31043 https://onlinelibrary.wiley.com/doi/10.1002/cncr.31043

PETERS S , FELIP E , DAFNI U , et al . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage ⅢA-B NSCLC: results from the European thoracic oncology platform NICOLAS phase Ⅱ trial (European thoracic oncology platform 6-14) [J ] . J Thorac Oncol , 2021 , 16 ( 2 ): 278 - 288 . DOI: 10.1016/j.jtho.2020.10.129 http://doi.org/10.1016/j.jtho.2020.10.129 https://linkinghub.elsevier.com/retrieve/pii/S1556086420309953 https://linkinghub.elsevier.com/retrieve/pii/S1556086420309953

LIN S H , LIN Y , YAO L Y , et al . Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC [J ] . J Thorac Oncol , 2020 , 15 ( 2 ): 248 - 257 . DOI: 10.1016/j.jtho.2019.10.024 http://doi.org/10.1016/j.jtho.2019.10.024 https://linkinghub.elsevier.com/retrieve/pii/S1556086419336597 https://linkinghub.elsevier.com/retrieve/pii/S1556086419336597

JABBOUR S K , BERMAN A T , DECKER R H , et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial [J ] . JAMA Oncol , 2020 , 6 ( 6 ): 848 - 855 . DOI: 10.1001/jamaoncol.2019.6731 http://doi.org/10.1001/jamaoncol.2019.6731 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761665 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761665

JABBOUR S K , LEE K H , FROST N , et al . Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial [J ] . JAMA Oncol , 2021 , 7 ( 9 ): 1 - 9 .

LEE Y J , AUH S L , WANG Y G , et al . Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment [J ] . Blood , 2009 , 114 ( 3 ): 589 - 595 .

GOUGH M J , CRITTENDEN M R , SARFF M , et al . Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice [J ] . J Immunother , 2010 , 33 ( 8 ): 798 - 809 . DOI: 10.1097/CJI.0b013e3181ee7095 http://doi.org/10.1097/CJI.0b013e3181ee7095 https://journals.lww.com/00002371-201010000-00006 https://journals.lww.com/00002371-201010000-00006

DEMARIA S , KAWASHIMA N , YANG A M , et al . Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer [J ] . Clin Cancer Res , 2005 , 11 ( 2 Pt 1 ): 728 - 734 . DOI: 10.1158/1078-0432.728.11.2 http://doi.org/10.1158/1078-0432.728.11.2 https://aacrjournals.org/clincancerres/article/11/2/728/186831/Immune-Mediated-Inhibition-of-Metastases-after https://aacrjournals.org/clincancerres/article/11/2/728/186831/Immune-Mediated-Inhibition-of-Metastases-after

FORDE P M , CHAFT J E , SMITH K N , et al . Neoadjuvant PD-1 blockade in resectable lung cancer [J ] . N Engl J Med , 2018 , 378 ( 21 ): 1976 - 1986 . DOI: 10.1056/NEJMoa1716078 http://doi.org/10.1056/NEJMoa1716078 http://www.nejm.org/doi/10.1056/NEJMoa1716078 http://www.nejm.org/doi/10.1056/NEJMoa1716078

YOST K E , SATPATHY A T , WELLS D K , et al . Clonal replacement of tumor-specific T cells following PD-1 blockade [J ] . Nat Med , 2019 , 25 ( 8 ): 1251 - 1259 . DOI: 10.1038/s41591-019-0522-3 http://doi.org/10.1038/s41591-019-0522-3 https://doi.org/10.1038/s41591-019-0522-3 https://doi.org/10.1038/s41591-019-0522-3

KATO R , HAYASHI H , CHIBA Y , et al . Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L) [J ] . J Immunother Cancer , 2020 , 8 ( 1 ): e000350.

SCHVARTSMAN G , PENG S A , BIS G , et al . Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer [J ] . Lung Cancer , 2017 , 112 : 90 - 95 . DOI: 10.1016/j.lungcan.2017.07.034 http://doi.org/10.1016/j.lungcan.2017.07.034 https://linkinghub.elsevier.com/retrieve/pii/S0169500217304336 https://linkinghub.elsevier.com/retrieve/pii/S0169500217304336

ROSS H J , KOZONO D E , URBANIC J J , et al . AFT-16: Phase Ⅱ trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage Ⅲ non-small cell lung cancer (NSCLC) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 8513 . DOI: 10.1200/JCO.2021.39.15_suppl.8513 http://doi.org/10.1200/JCO.2021.39.15_suppl.8513 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8513 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8513

BRAHMER J R . Harnessing the immune system for the treatment of non-small cell lung cancer [J ] . J Clin Oncol , 2013 , 31 ( 8 ): 1021 - 1028 . DOI: 10.1200/JCO.2012.45.8703 http://doi.org/10.1200/JCO.2012.45.8703 https://ascopubs.org/doi/10.1200/JCO.2012.45.8703 https://ascopubs.org/doi/10.1200/JCO.2012.45.8703

SWANN J B , SMYTH M J . Immune surveillance of tumors [J ] . J Clin Invest , 2007 , 117 ( 5 ): 1137 - 1146 . DOI: 10.1172/JCI31405 http://doi.org/10.1172/JCI31405 http://www.jci.org/cgi/doi/10.1172/JCI31405 http://www.jci.org/cgi/doi/10.1172/JCI31405

APETOH L , GHIRINGHELLI F , TESNIERE A , et al . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J ] . Nat Med , 2007 , 13 ( 9 ): 1050 - 1059 . DOI: 10.1038/nm1622 http://doi.org/10.1038/nm1622 http://www.nature.com/articles/nm1622 http://www.nature.com/articles/nm1622

FORMENTI S C , DEMARIA S . Combining radiotherapy and cancer immunotherapy: a paradigm shift [J ] . J Natl Cancer Inst , 2013 , 105 ( 4 ): 256 - 265 . DOI: 10.1093/jnci/djs629 http://doi.org/10.1093/jnci/djs629 https://academic.oup.com/jnci/article/105/4/256/926146 https://academic.oup.com/jnci/article/105/4/256/926146

LADBURY C J , RUSTHOVEN C G , CAMIDGE D R , et al . Impact of radiation dose to the host immune system on tumor control and survival for stage Ⅲ non-small cell lung cancer treated with definitive radiation therapy [J ] . Int J Radiat Oncol Biol Phys , 2019 , 105 ( 2 ): 346 - 355 . DOI: 10.1016/j.ijrobp.2019.05.064 http://doi.org/10.1016/j.ijrobp.2019.05.064 https://linkinghub.elsevier.com/retrieve/pii/S0360301619308181 https://linkinghub.elsevier.com/retrieve/pii/S0360301619308181

MATTES M D , EUBANK T D , ALMUBARAK M , et al . A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer [J ] . Clin Lung Cancer , 2021 , 22 ( 4 ): 268 - 273 . DOI: 10.1016/j.cllc.2021.01.012 http://doi.org/10.1016/j.cllc.2021.01.012 https://linkinghub.elsevier.com/retrieve/pii/S1525730421000152 https://linkinghub.elsevier.com/retrieve/pii/S1525730421000152

VENKATESULU B P , MALLICK S , LIN S H , et al . A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors [J ] . Crit Rev Oncol Hematol , 2018 , 123 : 42 - 51 . DOI: 10.1016/j.critrevonc.2018.01.003 http://doi.org/10.1016/j.critrevonc.2018.01.003 https://linkinghub.elsevier.com/retrieve/pii/S1040842817303499 https://linkinghub.elsevier.com/retrieve/pii/S1040842817303499

TANG C , LIAO Z X , GOMEZ D , et al . Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes [J ] . Int J Radiat Oncol Biol Phys , 2014 , 89 ( 5 ): 1084 - 1091 . DOI: 10.1016/j.ijrobp.2014.04.025 http://doi.org/10.1016/j.ijrobp.2014.04.025 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969 https://linkinghub.elsevier.com/retrieve/pii/S0360301614004969

CAMPIAN J L , YE X B , BROCK M , et al . Treatment-related lymphopenia in patients with stage Ⅲ non-small cell lung cancer [J ] . Cancer Invest , 2013 , 31 ( 3 ): 183 - 188 . DOI: 10.3109/07357907.2013.767342 http://doi.org/10.3109/07357907.2013.767342 http://www.tandfonline.com/doi/full/10.3109/07357907.2013.767342 http://www.tandfonline.com/doi/full/10.3109/07357907.2013.767342

CHO O , OH Y T , CHUN M , et al . Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer [J ] . Tumour Biol , 2016 , 37 ( 1 ): 971 - 978 . DOI: 10.1007/s13277-015-3888-y http://doi.org/10.1007/s13277-015-3888-y http://link.springer.com/10.1007/s13277-015-3888-y http://link.springer.com/10.1007/s13277-015-3888-y

FARHOOD B , NAJAFI M , MORTEZAEE K . CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review [J ] . J Cell Physiol , 2019 , 234 ( 6 ): 8509 - 8521 . DOI: 10.1002/jcp.27782 http://doi.org/10.1002/jcp.27782 https://onlinelibrary.wiley.com/doi/10.1002/jcp.27782 https://onlinelibrary.wiley.com/doi/10.1002/jcp.27782

BÖTTCHER J P , SOUSA C R E . The role of type 1 conventional dendritic cells in cancer immunity [J ] . Trends Cancer , 2018 , 4 ( 11 ): 784 - 792 . DOI: 10.1016/j.trecan.2018.09.001 http://doi.org/10.1016/j.trecan.2018.09.001 https://linkinghub.elsevier.com/retrieve/pii/S2405803318301948 https://linkinghub.elsevier.com/retrieve/pii/S2405803318301948

ABRAVAN A , FAIVRE-FINN C , KENNEDY J , et al . Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1624 - 1635 . DOI: 10.1016/j.jtho.2020.06.008 http://doi.org/10.1016/j.jtho.2020.06.008 https://linkinghub.elsevier.com/retrieve/pii/S1556086420304780 https://linkinghub.elsevier.com/retrieve/pii/S1556086420304780

LI R J , YU L , LIN S X , et al . Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF) [J ] . Radiat Oncol , 2016 , 11 ( 1 ): 124 . DOI: 10.1186/s13014-016-0698-3 http://doi.org/10.1186/s13014-016-0698-3 http://ro-journal.biomedcentral.com/articles/10.1186/s13014-016-0698-3 http://ro-journal.biomedcentral.com/articles/10.1186/s13014-016-0698-3

CHEN M , BAO Y , MA H L , et al . Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study [J ] . Biomed Res Int , 2013 , 2013 : 371819 .

SENAN S , BURGERS S , SAMSON M J , et al . Can elective nodal irradiation be omitted in stage Ⅲ non-small cell lung cancer? Analysis of recurrences in a phase Ⅱ study of induction chemotherapy and involved-field radiotherapy [J ] . Int J Radiat Oncol Biol Phys , 2002 , 54 ( 4 ): 999 - 1006 . DOI: 10.1016/S0360-3016(02)03028-6 http://doi.org/10.1016/S0360-3016(02)03028-6 https://linkinghub.elsevier.com/retrieve/pii/S0360301602030286 https://linkinghub.elsevier.com/retrieve/pii/S0360301602030286

ROSENZWEIG K E , SURA S , JACKSON A , et al . Involved-field radiation therapy for inoperable non-small cell lung cancer [J ] . J Clin Oncol , 2007 , 25 ( 35 ): 5557 - 5561 . DOI: 10.1200/JCO.2007.13.2191 http://doi.org/10.1200/JCO.2007.13.2191 https://ascopubs.org/doi/10.1200/JCO.2007.13.2191 https://ascopubs.org/doi/10.1200/JCO.2007.13.2191

FERNANDES A T , SHEN J , FINLAY J , et al . Elective nodal irradiation (ENI) vs involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes [J ] . Radiother Oncol , 2010 , 95 ( 2 ): 178 - 184 . DOI: 10.1016/j.radonc.2010.02.007 http://doi.org/10.1016/j.radonc.2010.02.007 https://linkinghub.elsevier.com/retrieve/pii/S0167814010000848 https://linkinghub.elsevier.com/retrieve/pii/S0167814010000848

YUAN S H , SUN X D , LI M H , et al . A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage Ⅲ nonsmall cell lung cancer [J ] . Am J Clin Oncol , 2007 , 30 ( 3 ): 239 - 244 . DOI: 10.1097/01.coc.0000256691.27796.24 http://doi.org/10.1097/01.coc.0000256691.27796.24 https://journals.lww.com/00000421-200706000-00005 https://journals.lww.com/00000421-200706000-00005

TOPKAN E , OZDEMIR Y , GULER O C , et al . Comparison of involved field radiotherapy versus elective nodal irradiation in stage ⅢB/C non-small cell lung carcinoma patients treated with concurrent chemoradiotherapy: a propensity score matching study [J ] . J Oncol , 2020 , 2020 : 7083149.

WITHERS H R , PETERS L J , TAYLOR J M G . Dose-response relationship for radiation therapy of subclinical disease [J ] . Int J Radiat Oncol , 1995 , 31 ( 2 ): 353 - 359 . DOI: 10.1016/0360-3016(94)00354-N http://doi.org/10.1016/0360-3016(94)00354-N https://linkinghub.elsevier.com/retrieve/pii/036030169400354N https://linkinghub.elsevier.com/retrieve/pii/036030169400354N

WITHERS H R , SUWINSKI R . Radiation dose response for subclinical metastases [J ] . Semin Radiat Oncol , 1998 , 8 ( 3 ): 224 - 228 . DOI: 10.1016/S1053-4296(98)80048-9 http://doi.org/10.1016/S1053-4296(98)80048-9 https://linkinghub.elsevier.com/retrieve/pii/S1053429698800489 https://linkinghub.elsevier.com/retrieve/pii/S1053429698800489

XIA F , ZHOU L J , YANG X , et al . Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? A dosimetric evaluation of three different treatment plans [J ] . J Thorac Dis , 2017 , 9 ( 12 ): 5194 - 5202 . DOI: 10.21037/jtd.2017.10.147 http://doi.org/10.21037/jtd.2017.10.147 http://jtd.amegroups.com/article/view/17167/14315 http://jtd.amegroups.com/article/view/17167/14315

ZOU L Q , CHU L , XIA F , et al . Is clinical target volume necessary? A failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique [J ] . Transl Lung Cancer Res , 2020 , 9 ( 5 ): 1986 - 1995 . DOI: 10.21037/tlcr-20-523 http://doi.org/10.21037/tlcr-20-523 http://tlcr.amegroups.com/article/view/42241/html http://tlcr.amegroups.com/article/view/42241/html

LIANG X C , YU H M , YU R , et al . Efficacy of the smaller target volume for stage Ⅲ non-small cell lung cancer treated with intensity-modulated radiotherapy [J ] . Mol Clin Oncol , 2015 , 3 ( 5 ): 1172 - 1176 . DOI: 10.3892/mco.2015.588 http://doi.org/10.3892/mco.2015.588 https://www.spandidos-publications.com/10.3892/mco.2015.588 https://www.spandidos-publications.com/10.3892/mco.2015.588

KILBURN J M , LUCAS J T , SOIKE M H , et al . Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)? [J ] . Cureus , 2016 , 8 ( 1 ): e466.

JIANG C X , HAN S Y , CHEN W C , et al . A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . Oncotarget , 2018 , 9 ( 15 ): 12443 - 12451 . DOI: 10.18632/oncotarget.23849 http://doi.org/10.18632/oncotarget.23849 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23849 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23849

MORISADA M , CLAVIJO P E , MOORE E , et al . PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation [J ] . Oncoimmunology , 2017 , 7 ( 3 ): e1395996.

ZHANG T , YU H F , NI C , et al . Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage Ⅰ non-small cell lung cancer [J ] . Sci Rep , 2017 , 7 ( 1 ): 4866 . DOI: 10.1038/s41598-017-04978-x http://doi.org/10.1038/s41598-017-04978-x http://www.nature.com/articles/s41598-017-04978-x http://www.nature.com/articles/s41598-017-04978-x

PAVLOPOULOU A , BAGOS P G , KOUTSANDREA V , et al . Molecular determinants of radiosensitivity in normal and tumor tissue: a bioinformatic approach [J ] . Cancer Lett , 2017 , 403 : 37 - 47 . DOI: 10.1016/j.canlet.2017.05.023 http://doi.org/10.1016/j.canlet.2017.05.023 https://linkinghub.elsevier.com/retrieve/pii/S0304383517303695 https://linkinghub.elsevier.com/retrieve/pii/S0304383517303695

KERNS S L , FACHAL L , DORLING L , et al . Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy [J ] . J Natl Cancer Inst , 2020 , 112 ( 2 ): 179 - 190 . DOI: 10.1093/jnci/djz075 http://doi.org/10.1093/jnci/djz075 https://academic.oup.com/jnci/article/112/2/179/5490201 https://academic.oup.com/jnci/article/112/2/179/5490201

BERNICHON E , VALLARD A , WANG Q , et al . Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol [J ] . Ann Oncol , 2017 , 28 ( 11 ): 2773 - 2779 . DOI: 10.1093/annonc/mdx488 http://doi.org/10.1093/annonc/mdx488 https://linkinghub.elsevier.com/retrieve/pii/S0923753419346071 https://linkinghub.elsevier.com/retrieve/pii/S0923753419346071

AHMED K A , BERGLUND A E , WELSH E A , et al . The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity [J ] . Neuro Oncol , 2017 , 19 ( 8 ): 1145 - 1146 . DOI: 10.1093/neuonc/nox043 http://doi.org/10.1093/neuonc/nox043 https://academic.oup.com/neuro-oncology/article/19/8/1145/3096451 https://academic.oup.com/neuro-oncology/article/19/8/1145/3096451

JIN J Y , WANG W L , TEN HAKEN R K , et al . Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer [J ] . Radiother Oncol , 2015 , 117 ( 1 ): 77 - 82 . DOI: 10.1016/j.radonc.2015.07.024 http://doi.org/10.1016/j.radonc.2015.07.024 https://linkinghub.elsevier.com/retrieve/pii/S0167814015003783 https://linkinghub.elsevier.com/retrieve/pii/S0167814015003783

LEE Y S , OH J H , YOON S , et al . Differential gene expression profiles of radioresistant non-small cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation [J ] . Int J Radiat Oncol Biol Phys , 2010 , 77 ( 3 ): 858 - 866 . DOI: 10.1016/j.ijrobp.2009.12.076 http://doi.org/10.1016/j.ijrobp.2009.12.076 https://linkinghub.elsevier.com/retrieve/pii/S036030161000129X https://linkinghub.elsevier.com/retrieve/pii/S036030161000129X

EDVARDSEN H , TEFRE T , JANSEN L , et al . Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence [J ] . Radiat Oncol , 2007 , 2 : 25 . DOI: 10.1186/1748-717X-2-25 http://doi.org/10.1186/1748-717X-2-25 https://doi.org/10.1186/1748-717X-2-25 https://doi.org/10.1186/1748-717X-2-25

SAK A , STUEBEN G , GRONEBERG M , et al . Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines [J ] . Br J Cancer , 2005 , 92 ( 6 ): 1089 - 1097 . DOI: 10.1038/sj.bjc.6602457 http://doi.org/10.1038/sj.bjc.6602457 https://doi.org/10.1038/sj.bjc.6602457 https://doi.org/10.1038/sj.bjc.6602457

SITTHIDEATPHAIBOON P , GALAN-COBO A , NEGRAO M V , et al . STK11/LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition [J ] . Clin Cancer Res , 2021 , 27 ( 6 ): 1720 - 1733 . DOI: 10.1158/1078-0432.CCR-20-2859 http://doi.org/10.1158/1078-0432.CCR-20-2859 https://aacrjournals.org/clincancerres/article/27/6/1720/671868/STK11-LKB1-Mutations-in-NSCLC-Are-Associated-with https://aacrjournals.org/clincancerres/article/27/6/1720/671868/STK11-LKB1-Mutations-in-NSCLC-Are-Associated-with

ESCHRICH S A , PRAMANA J , ZHANG H L , et al . A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation [J ] . Int J Radiat Oncol Biol Phys , 2009 , 75 ( 2 ): 489 - 496 . DOI: 10.1016/j.ijrobp.2009.06.014 http://doi.org/10.1016/j.ijrobp.2009.06.014 https://linkinghub.elsevier.com/retrieve/pii/S0360301609009195 https://linkinghub.elsevier.com/retrieve/pii/S0360301609009195

ESCHRICH S , ZHANG H L , ZHAO H Y , et al . Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform [J ] . Int J Radiat Oncol Biol Phys , 2009 , 75 ( 2 ): 497 - 505 . DOI: 10.1016/j.ijrobp.2009.05.056 http://doi.org/10.1016/j.ijrobp.2009.05.056 https://linkinghub.elsevier.com/retrieve/pii/S036030160900830X https://linkinghub.elsevier.com/retrieve/pii/S036030160900830X

TORRES-ROCA J F , ESCHRICH S , ZHAO H Y , et al . Prediction of radiation sensitivity using a gene expression classifier [J ] . Cancer Res , 2005 , 65 ( 16 ): 7169 - 7176 . DOI: 10.1158/0008-5472.CAN-05-0656 http://doi.org/10.1158/0008-5472.CAN-05-0656 https://aacrjournals.org/cancerres/article/65/16/7169/518226/Prediction-of-Radiation-Sensitivity-Using-a-Gene https://aacrjournals.org/cancerres/article/65/16/7169/518226/Prediction-of-Radiation-Sensitivity-Using-a-Gene

SCOTT J G , BERGLUND A , SCHELL M J , et al . A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study [J ] . Lancet Oncol , 2017 , 18 ( 2 ): 202 - 211 . DOI: 10.1016/S1470-2045(16)30648-9 http://doi.org/10.1016/S1470-2045(16)30648-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204516306489 https://linkinghub.elsevier.com/retrieve/pii/S1470204516306489

AHMED K A , LIVERINGHOUSE C L , MILLS M N , et al . Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management [J ] . EBioMedicine , 2019 , 47 : 163 - 169 . DOI: 10.1016/j.ebiom.2019.08.019 http://doi.org/10.1016/j.ebiom.2019.08.019 https://linkinghub.elsevier.com/retrieve/pii/S2352396419305377 https://linkinghub.elsevier.com/retrieve/pii/S2352396419305377

OLIVER D E , MOHAMMADI H , FIGURA N , et al . Novel genomic-based strategies to personalize lymph node radiation therapy [J ] . Semin Radiat Oncol , 2019 , 29 ( 2 ): 111 - 125 . DOI: 10.1016/j.semradonc.2018.11.003 http://doi.org/10.1016/j.semradonc.2018.11.003 https://linkinghub.elsevier.com/retrieve/pii/S1053429618300997 https://linkinghub.elsevier.com/retrieve/pii/S1053429618300997

SCOTT J G , SEDOR G , ELLSWORTH P , et al . Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis [J ] . Lancet Oncol , 2021 , 22 ( 9 ): 1221 - 1229 . DOI: 10.1016/S1470-2045(21)00347-8 http://doi.org/10.1016/S1470-2045(21)00347-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204521003478 https://linkinghub.elsevier.com/retrieve/pii/S1470204521003478

SCOTT J G , SEDOR G , SCARBOROUGH J A , et al . Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 3 ): 428 - 438 . DOI: 10.1016/j.jtho.2020.11.008 http://doi.org/10.1016/j.jtho.2020.11.008 https://linkinghub.elsevier.com/retrieve/pii/S1556086420310467 https://linkinghub.elsevier.com/retrieve/pii/S1556086420310467

NICHOLS R C , HUH S N , HENDERSON R H , et al . Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage Ⅲ non-small cell lung cancer: a dosimetric study [J ] . Clin Lung Cancer , 2011 , 12 ( 4 ): 252 - 257 . DOI: 10.1016/j.cllc.2011.03.027 http://doi.org/10.1016/j.cllc.2011.03.027 https://linkinghub.elsevier.com/retrieve/pii/S1525730411000283 https://linkinghub.elsevier.com/retrieve/pii/S1525730411000283

HIGGINS K A , O'CONNELL K , LIU Y , et al . National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer [J ] . Int J Radiat Oncol Biol Phys , 2017 , 97 ( 1 ): 128 - 137 . DOI: 10.1016/j.ijrobp.2016.10.001 http://doi.org/10.1016/j.ijrobp.2016.10.001 https://linkinghub.elsevier.com/retrieve/pii/S0360301616332758 https://linkinghub.elsevier.com/retrieve/pii/S0360301616332758

GJYSHI O , XU T , ELHAMMALI A , et al . Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 2 ): 269 - 277 . DOI: 10.1016/j.jtho.2020.10.013 http://doi.org/10.1016/j.jtho.2020.10.013 https://linkinghub.elsevier.com/retrieve/pii/S155608642030839X https://linkinghub.elsevier.com/retrieve/pii/S155608642030839X

LIAO Z X , LEE J J , KOMAKI R , et al . Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small cell lung cancer [J ] . J Clin Oncol , 2018 , 36 ( 18 ): 1813 - 1822 . DOI: 10.1200/JCO.2017.74.0720 http://doi.org/10.1200/JCO.2017.74.0720 https://ascopubs.org/doi/10.1200/JCO.2017.74.0720 https://ascopubs.org/doi/10.1200/JCO.2017.74.0720

TAKAHASHI W , NAKAJIMA M , YAMAMOTO N , et al . A prospective nonrandomized phase Ⅰ/Ⅱ study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC) [J ] . Cancer , 2015 , 121 ( 8 ): 1321 - 1327 . DOI: 10.1002/cncr.29195 http://doi.org/10.1002/cncr.29195 https://onlinelibrary.wiley.com/doi/10.1002/cncr.29195 https://onlinelibrary.wiley.com/doi/10.1002/cncr.29195

ONISHI M , OKONOGI N , OIKE T , et al . High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cells [J ] . J Radiat Res , 2018 , 59 ( 5 ): 541 - 546 . DOI: 10.1093/jrr/rry049 http://doi.org/10.1093/jrr/rry049 https://academic.oup.com/jrr/article/59/5/541/5045655 https://academic.oup.com/jrr/article/59/5/541/5045655

ANDO K , FUJITA H , HOSOI A , et al . Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation [J ] . J Radiat Res , 2017 , 58 ( 4 ): 446 - 455 . DOI: 10.1093/jrr/rrx005 http://doi.org/10.1093/jrr/rrx005 https://academic.oup.com/jrr/article/58/4/446/3055267 https://academic.oup.com/jrr/article/58/4/446/3055267

BROWNSTEIN J M , WISDOM A J , CASTLE K D , et al . Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma [J ] . Mol Cancer Ther , 2018 , 17 ( 4 ): 858 - 868 . DOI: 10.1158/1535-7163.MCT-17-0965 http://doi.org/10.1158/1535-7163.MCT-17-0965 https://aacrjournals.org/mct/article/17/4/858/92417/Characterizing-the-Potency-and-Impact-of-Carbon https://aacrjournals.org/mct/article/17/4/858/92417/Characterizing-the-Potency-and-Impact-of-Carbon